Taniguchi Toru, Inagaki Hiroaki, Baba Daichi, Yasumatsu Isao, Toyota Akiko, Kaneta Yasuyuki, Kiga Masaki, Iimura Shin, Odagiri Takashi, Shibata Yoshihiro, Ueda Kiyono, Seo Maki, Shimizu Hiroki, Imaoka Tomoki, Nakayama Kiyoshi
R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Daiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan.
ACS Med Chem Lett. 2019 Mar 15;10(5):737-742. doi: 10.1021/acsmedchemlett.8b00631. eCollection 2019 May 9.
To obtain a new anticancer drug, we focused on FER tyrosine kinase. Starting with high-throughput screening with our in-house chemical library, compound , which has a pyridine moiety, was found. Referring to their X-ray crystal structure with FES proto-oncogene tyrosine kinase, as a surrogate of FER followed by chemical modification including scaffold hopping of the pyridine template, we discovered pyrido-pyridazinone derivatives with potent FER kinase inhibitory activity. Here, we disclose the structure-activity relationship on the scaffold and representative compound (), which showed antitumor efficacy in a subcutaneous tumor model.
为了获得一种新的抗癌药物,我们聚焦于FER酪氨酸激酶。从使用我们内部化学文库进行高通量筛选开始,发现了具有吡啶部分的化合物 。参考其与FES原癌基因酪氨酸激酶的X射线晶体结构(作为FER的替代物),随后进行化学修饰,包括吡啶模板的骨架跃迁,我们发现了具有强效FER激酶抑制活性的吡啶并哒嗪酮衍生物。在此,我们揭示了该骨架的构效关系以及代表性化合物 (),其在皮下肿瘤模型中显示出抗肿瘤功效。